miR-29b participates in early aneurysm development in Marfan syndrome

Circ Res. 2012 Jan 20;110(2):312-24. doi: 10.1161/CIRCRESAHA.111.253740. Epub 2011 Nov 23.

Abstract

Rationale: Marfan syndrome (MFS) is a systemic connective tissue disorder notable for the development of aortic root aneurysms and the subsequent life-threatening complications of aortic dissection and rupture. Underlying fibrillin-1 gene mutations cause increased transforming growth factor-β (TGF-β) signaling. Although TGF-β blockade prevents aneurysms in MFS mouse models, the mechanisms through which excessive TGF-β causes aneurysms remain ill-defined.

Objective: We investigated the role of microRNA-29b (miR-29b) in aneurysm formation in MFS.

Methods and results: Using quantitative polymerase chain reaction, we discovered that miR-29b, a microRNA regulating apoptosis and extracellular matrix synthesis/deposition genes, is increased in the ascending aorta of Marfan (Fbn1(C1039G/+)) mice. Increased apoptosis, assessed by increased cleaved caspase-3 and caspase-9, enhanced caspase-3 activity, and decreased levels of the antiapoptotic proteins, Mcl-1 and Bcl-2, were found in the Fbn1(C1039G/+) aorta. Histological evidence of decreased and fragmented elastin was observed exclusively in the Fbn1(C1039G/+) ascending aorta in association with repressed elastin mRNA and increased matrix metalloproteinase-2 expression and activity, both targets of miR-29b. Evidence of decreased activation of nuclear factor κB, a repressor of miR-29b, and a factor suppressed by TGF-β, was also observed in Fbn1(C1039G/+) aorta. Furthermore, administration of a nuclear factor κB inhibitor increased miR-29b levels, whereas TGF-β blockade or losartan effectively decreased miR-29b levels in Fbn1(C1039G/+) mice. Finally, miR-29b blockade by locked nucleic acid antisense oligonucleotides prevented early aneurysm development, aortic wall apoptosis, and extracellular matrix deficiencies.

Conclusions: We identify increased miR-29b expression as key to the pathogenesis of early aneurysm development in MFS by regulating aortic wall apoptosis and extracellular matrix abnormalities.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Animals
  • Aorta / metabolism*
  • Aorta / pathology
  • Aortic Aneurysm / genetics
  • Aortic Aneurysm / metabolism*
  • Aortic Aneurysm / pathology
  • Aortic Aneurysm / prevention & control
  • Apoptosis
  • Apoptosis Regulatory Proteins / metabolism
  • Cells, Cultured
  • Disease Models, Animal
  • Elastin / genetics
  • Elastin / metabolism
  • Female
  • Fibrillin-1
  • Fibrillins
  • Genetic Therapy / methods
  • Losartan / pharmacology
  • Male
  • Marfan Syndrome / complications
  • Marfan Syndrome / genetics
  • Marfan Syndrome / metabolism*
  • Marfan Syndrome / pathology
  • Marfan Syndrome / therapy
  • Matrix Metalloproteinase 2 / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • MicroRNAs / genetics
  • MicroRNAs / metabolism*
  • Microfilament Proteins / genetics
  • Microfilament Proteins / metabolism
  • NF-kappa B / metabolism
  • Oligonucleotides, Antisense / administration & dosage
  • Real-Time Polymerase Chain Reaction
  • Reverse Transcriptase Polymerase Chain Reaction
  • Transforming Growth Factor beta / metabolism
  • Up-Regulation

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Apoptosis Regulatory Proteins
  • Fbn1 protein, mouse
  • Fibrillin-1
  • Fibrillins
  • MIRN29 microRNA, mouse
  • MicroRNAs
  • Microfilament Proteins
  • NF-kappa B
  • Oligonucleotides, Antisense
  • Transforming Growth Factor beta
  • Elastin
  • Matrix Metalloproteinase 2
  • Mmp2 protein, mouse
  • Losartan